- Alba by Quotient: Revenues exceeded guidance; Achieved year-over year growth in Q2 FY 2022 of 15.9%
- Financial Position: Available cash & short-term investments of $141.8 million
- Business Update: Communication issued on November 9, 2021; providing a progress update on development and upcoming commercialization
JERSEY, Channel Islands, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its financial results for the second quarter of fiscal year 2022 and filed the quarterly report on Form 10-Q.
Alba by Quotient: Revenues exceeded guidance and continued to drive double digit growth. Generated $9.2 million product sales in the second quarter, growing 15.9% over Q2 of FY 2021. Alba’s sales to OEM customers grew 18.6% versus a decline of -5.3% in the first quarter year-over-year.
Financial Position: The Company reports a solid cash position with a total of cash and short-term investments of $141.8 that will allow the company to continue to develop the MosaiQ pipeline and execute on the European launch of the MosaiQ platform as soon as the Immunohematology CE mark is obtained.
During the Quarter, a total payout of $11.2 million related to the Credit Suisse Supply Chain Finance funds was received.
Subsequent to the end of the second quarter of FY 2022, the Company successfully amended the Senior Notes Indenture, postponing principal payments by 18 months and reducing the Company’s near-term cash obligations by approximately $60 million over the next two years.
Form 10-K/A and Form 10-Q/A restatements
On November 15, the Company filed an amended Form 10-K for the fiscal year ended March 31, 2021 and an amended Form 10-Q’s for the quarter ended June 30, 2021, which reflected restated financial statements in connection with the previously announced non-cash adjustment in connection to its Senior Secured Notes and related royalty rights agreements. The adjustment amounted to approximately $0.2 million in FY2019, $3.0 million in FY 2020, $3.9 million in FY 2021 and $2.4 million in the first quarter of FY 2022 in non-cash interest expenses and increase in long term liabilities.
Fiscal Second Quarter Financial Results
The Alba by Quotient reagent business exceeded guidance and generated product sales of $9.2 million in the second quarter of FY 2022, up 15.9% from the quarter ended September 30, 2020. OEM sales increased by 18.6% and sales to direct customers and distributors were up 11.5% vs. Q2 FY 2021. In the quarter ended September 30, 2021, gross margin on product sales was at 47.5% compared to the gross margin of 47.3% reported in the quarter ended September 30, 2020.
Key revenue and profit results are summarized below (expressed in thousands, except percentages).
Total Operating expenses for the quarter increased by $3.9 million or 15.8% compared to the second quarter of the prior fiscal year. This increase is primarily driven by higher R&D spend related to the ongoing MosaiQ Field Trials.
Capital expenditures totaled $0.3 million in the quarter ended September 30, 2021, compared with $1.3 million in the quarter ended September 30, 2020.
Interest expense for the quarter increased by $3.1 million compared to Q2 of FY 2021. The increase in interest expense is primarily due to higher interest cost related to the convertible debt.
As at September 30, 2021 Quotient had $141.8 million in cash and other short-term investments and $232 million of debt and $8.3 million in an offsetting long-term cash reserve account.
Outlook for the Fiscal Year Ending March 31, 2022, remains unchanged
- Total product sales of Alba by Quotient reagents continue to be expected in the range of $35.5 to $36.5 million compared to product sales in FY 2021 of $34.5 million. No other revenues are expected.
- Capital expenditures in the range of $5 to $10 million.
- Average monthly cash use for operations in the range of $6.5 to $7 million (excluding debt service cost and capital expenditures)
Alba by Quotient product sales in the third quarter of FY 2022 are expected to be within the range of $9.1 to $9.7 million, compared with $8.4 million for the second quarter of FY 2021.
The Company is not providing guidance on the operating loss.
Quarterly product sales can fluctuate depending upon the shipment cycles for red blood cell-based products, which account for approximately two-thirds of current product sales. These products typically experience 13 shipment cycles per year, equating to three shipments of each product per quarter, except for one quarter per year when four shipments occur. The timing of shipment of bulk antisera products to OEM customers may also move revenues from quarter to quarter. Some seasonality in demand is also experienced around holiday periods in both Europe and the United States. As a result of these factors, Quotient expects to continue to see seasonality and quarter-to-quarter variations in product sales.
About Quotient Limited
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient's operations are based in Eysins, Switzerland, and Edinburgh, Scotland, and Newtown, Pennsylvania.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ and other new products (including the potential for using the Company’s MosaiQ technology to infectious disease diagnostics), current estimates of third quarter and full year fiscal 2022 operating results and expectations regarding our future funding sources. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceedings; continued or worsening adverse conditions in the general domestic and global economic markets, including as a result of the global COVID-19 pandemic; as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements.
The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
Condensed Consolidated Statements of Comprehensive Loss
(in thousands, except share and per share amounts)
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Cash Flows